Abstract:BACKGROUND:Heart failure (HF) with preserved ejection fraction (HFpEF) constitutes half of all HF but lacks effective therapy. Understanding of its myocardial biology remains limited because of a paucity of heart tissue molecular analysis.METHODS:We performed RNA sequencing on right ventricular septal endomyocardial biopsies prospectively obtained from patients meeting consensus criteria for HFpEF (n=41) contrasted with right ventricular septal tissue from patients with HF with reduced ejection fraction (HFrEF, n=30) and donor controls (n=24). Principal component analysis and hierarchical clustering tested for transcriptomic distinctiveness between groups, effect of comorbidities, and differential gene expression with pathway enrichment contrasted HF groups and donor controls. Within HFpEF, non-negative matrix factorization and weighted gene coexpression analysis identified molecular subgroups, and the resulting clusters were correlated with hemodynamic and clinical data.RESULTS:Patients with HFpEF were more often women (59%), African American (68%), obese (median body mass index 41), and hypertensive (98%), with clinical HF characterized by 65% New York Heart Association Class III or IV, nearly all on a loop diuretic, and 70% with a HF hospitalization in the previous year. Principal component analysis separated HFpEF from HFrEF and donor controls with minimal overlap, and this persisted after adjusting for primary comorbidities: body mass index, sex, age, diabetes, and renal function. Hierarchical clustering confirmed group separation. Nearly half the significantly altered genes in HFpEF versus donor controls (1882 up, 2593 down) changed in the same direction in HFrEF; however, 5745 genes were uniquely altered between HF groups. Compared with controls, uniquely upregulated genes in HFpEF were enriched in mitochondrial adenosine triphosphate synthesis/electron transport, pathways downregulated in HFrEF. HFpEF-specific downregulated genes engaged endoplasmic reticulum stress, autophagy, and angiogenesis. Body mass index differences largely accounted for HFpEF upregulated genes, whereas neither this nor broader comorbidity adjustment altered pathways enriched in downregulated genes. Non-negative matrix factorization identified 3 HFpEF transcriptomic subgroups with distinctive pathways and clinical correlates, including a group closest to HFrEF with higher mortality, and a mostly female group with smaller hearts and proinflammatory signaling. These groupings remained after sex adjustment. Weighted gene coexpression analysis yielded analogous gene clusters and clinical groupings.CONCLUSIONS:HFpEF exhibits distinctive broad transcriptomic signatures and molecular subgroupings with particular clinical features and outcomes. The data reveal new signaling targets to consider for precision therapeutics.

Connecting intermediate phenotypes to disease using multi-omics in heart failure

Heart failure: advanced development in genetics and epigenetics.

Multi-trait genome-wide analysis identified novel risk loci and candidate drugs for heart failure

Multi-omics integration to identify the genetic expression and protein signature of dilated and ischemic cardiomyopathy

Morphometric, Hemodynamic, And Multi-Omics Analyses In Heart Failure Rats With Preserved Ejection Fraction

A cross-study transcriptional patient map of heart failure defines conserved multicellular coordination in cardiac remodeling

Myocardial Gene Expression Signatures in Human Heart Failure with Preserved Ejection Fraction

Clinical-transcriptional prioritization of the circulating proteome in human heart failure

Unravelling the genetic basis of heart failure via systems genetics.

Genome wide association study provides new insights into the genetic architecture and pathogenesis of heart failure

The Genetic Factors Influencing Cardiomyopathies and Heart Failure across the Allele Frequency Spectrum

Large-scale Mendelian randomization identifies novel pathways as therapeutic targets for heart failure with reduced ejection fraction and with preserved ejection fraction

Dissecting Regulatory Non-Coding Heart Disease GWAS Loci with High-Resolution 3D Chromatin Interactions Reveals Causal Genes with Pathophysiological Relevance to Heart Failure

Biological Pathways and Gene Networks Link Inflammation and Vascular Remodeling to Both Heart Failure with Preserved and Reduced Ejection Fraction in Women across Ethnicities

Identification of biomarkers, pathways, and potential therapeutic targets for heart failure using next-generation sequencing data and bioinformatics analysis

Integrative Analysis of Bulk and Single-Cell RNA Sequencing Data Reveals Cell Types Involved in Heart Failure

Common- and rare-variant genetic architecture of heart failure across the allele frequency spectrum

Large scale plasma proteomics identifies novel proteins and protein networks associated with heart failure development

Whole-genome profiling highlights the molecular complexity underlying eccentric cardiac hypertrophy.

A meta-analysis approach to gene regulatory network inference identifies key regulators of cardiovascular diseases

Using Model‐Based Analysis and Physiology‐Informed Machine Learning to Refine the Stratification of Phenotypes in Heart Failure